Belzutifan is a type of inhibitor for VHL-related RCC treatment. It’s a pseudo-inhibitor targeting HIF-2α. It helps by cutting down on the tumor’s lack of oxygen signals.
The drug comes in 40 mg film-coated tablets. The dose you should take is 120 mg every day. Each bottle has 90 tablets in it.
Reviews
There are no reviews yet.